Literature DB >> 9809989

Retinoic acid down-regulates the expression of the vasoactive intestinal polypeptide receptor type-1 in human breast carcinoma cell lines.

B Madsen1, B Georg, H Vissing, J Fahrenkrug.   

Abstract

Four breast carcinoma cell lines (T47D, ZR-75-1, MDA-MB-231, and MCF-7) were tested for regulation of the expression of vasoactive intestinal polypeptide receptor type-1 (VIP-R1). In all four cell lines, retinoic acid (RA) treatment caused a fast and marked decrease in VIP-R1 mRNA level as examined by Northern blots. Cycloheximide pretreatment attenuated the effect from 3- to 2-fold, indicating that existing proteins can mediate the decreasing effect of RA, but to attain the maximal effect new protein synthesis might be needed. Transcriptional inhibition with Actinomyocin D showed that RA did not influence the VIP-R1 mRNA half-life, indicating that the decreasing effect of RA on the mRNA level is due to transcriptional inhibition. In agreement with the observations on mRNA level, we found that the VIP receptor number was reduced 3-fold from 88 to 32 fmol/10(6) cells in T47D cells and from 222 to 73 fmol/10(6) cells in MDA-MB-231 cells upon RA treatment for 72 h. The promoter and 5'-flanking region of the VIP-R1 gene were cloned from a human placental cosmid library, and 2.5 kb were sequenced to search for regulatory elements. Our results, therefore, imply that the regulation of VIP-R1 gene expression by RA could have a role in human mammary tumor biology.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9809989

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  5 in total

1.  Antitumorigenic actions of growth hormone-releasing hormone antagonists.

Authors:  R D Kineman
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-18       Impact factor: 11.205

2.  The human vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor 1 (VPAC1) promoter: characterization and role in receptor expression during enterocytic differentiation of the colon cancer cell line Caco-2Cl.20.

Authors:  A Couvineau; J J Maoret; C Rouyer-Fessard; I Carrero; M Laburthe
Journal:  Biochem J       Date:  2000-05-01       Impact factor: 3.857

Review 3.  Vasoactive intestinal peptide/pituitary adenylate cyclase activating polypeptide, and their receptors and cancer.

Authors:  Terry W Moody; Bernardo Nuche-Berenguer; Robert T Jensen
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2016-02       Impact factor: 3.243

4.  Retinol supplements antiviral action of interferon in patients with chronic hepatitis C: a prospective pilot study.

Authors:  Naruaki Kohge; Shuichi Sato; Sachiko Hamamoto; Shuji Akagi; Yasushi Uchida; Tatsuya Miyake; Tomoko Mishiro; Kohichiro Furuta; Naoki Oshima; Junnichi Ishine; Yoshiko Takahashi; Norihisa Ishimura; Ryo Fukuda; Shunji Ishihara; Yuji Amano; Yoshikazu Kinoshita
Journal:  J Clin Biochem Nutr       Date:  2009-12-29       Impact factor: 3.114

Review 5.  Neuropeptide G Protein-Coupled Receptors as Oncotargets.

Authors:  Terry W Moody; Irene Ramos-Alvarez; Robert T Jensen
Journal:  Front Endocrinol (Lausanne)       Date:  2018-06-29       Impact factor: 5.555

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.